The EU TransPharm project aims to support the transition towards the production and use of more sustainable pharmaceuticals. TransPharm will develop a new methodology to assess the sustainability of pharmaceuticals over their entire life cycle, building upon existing approaches of lifecycle assessment (LCA) and chemical risk assessment. The methodology will integrate sustainability aspects related to the design and production of pharmaceuticals with those related to their use and disposal, including risk mitigation measures. The methodology will build upon the latest scientific insights and be specifically tailored to the needs of potential users such as regulators, industry and the health sector. Specific objectives are:
• To map the value chain of pharmaceuticals, identify environmental impacts and sustainability issues, and decide in collaboration with stakeholders which issues should be included in the integrated sustainability assessment.
• To develop methodological innovations to improve the sustainability assessment of the entire pharmaceutical value chain addressing specific challenges such as scarcity of life cycle inventory (LCI) data, lacking characterisation factors for ecotoxicity, spatial distribution of the value chain, and the inclusion of socioeconomic considerations.
• To integrate innovations for sustainability assessment and demonstrate how this approach can be operationalised in practice, for example in procurement, market approval and production planning.

The above-mentioned tasks will be performed in close collaboration between the two PhD candidates, a postdoctoral researchers on a three-year contract, and several other TransPharm project partners. The division of tasks between the two PhDs is still to be determined, but we expect one PhD candidate to focus on the challenges in lifecycle assessment of pharmaceuticals (e.g. scarcity of life cycle inventory data, the spatial distribution of the value chain, and the inclusion of socioeconomic considerations) and the other PhD candidate more on assessing the ecotoxic impacts of pharmaceuticals (e.g. the development of new characterisation factors). Your teaching load may be up to 10% of your appointment.